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Abstract
Background: Pilocytic astrocytomas (PAs) are the most common pediatric central nervous system neoplasms. In
the majority of cases these tumors are benign and receive favorable prognosis following gross total surgical
resection. In patients with progressive or symptomatic tumors, aggressive surgical resection is generally not feasible,
thus radiation or chemotherapy are accepted initial or adjuvant interventions. Due to serious long-lasting side-
effects, radiation is limited in young children; therefore, chemotherapy is widely practiced as an adjuvant treatment
for these patients. However, chemotherapy can promote the emergence of multidrug resistant tumor cells that are
more malignant than those of the original tumor. CD133, a putative stem cell marker in normal tissue and
malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult
malignant glioblastomas. This study examines the relationship between CD133 and MDR1 in pediatric PAs exposed
to chemotherapy, with the goal of identifying therapeutic targets that manifest as a result of chemotherapy.
Methods: Slides were obtained for 15 recurrent PAs, seven of which had received chemotherapy prior to surgical
treatment for the recurrent tumor. These samples, as well as primary tumor tissue slides from the same patients
were used to investigate CD133 and MDR1 expression via immunofluorescence. Archived frozen tissue samples
from the same patients were used to examine CD133, MDR1 and PI3K-Akt-NF-κB signaling mediators, via western
blot. Two drug resistant pediatric PA cell lines Res186 and Res199 were also used to evaluate the role of CD133 on
cell response to cytotoxic therapy.
Results: CD133 and MDR1 were co-expressed and their expression was elevated in recurrent PAs from patients that
had received chemotherapy, compared to patients that had not received chemotherapy. PI3K-Akt-NF-κB signaling
mediator expression was also elevated in recurrent, chemotherapy-treated PA. Suppressing CD133 expression with
siCD133 decreased levels of PI3K-Akt-NF-κB signaling mediators and MDR1, while increasing cell chemosensitivity,
as indicated by quantification of apoptotic cells following chemotherapy.
Conclusions: CD133 contributes to multidrug resistance by regulating MDR1 levels via the PI3K-Akt-NF-κB signal
pathway not only in adult glioblastomas, but also in pediatric PAs. Targeting CD133, adjuvant to conventional
chemotherapy may improve outcomes for children with recurrent PA.
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Background
Pilocytic astrocytomas (PAs), frequently seen in children
and young adults, are the most common pediatric central
nervous system (CNS) neoplasm [1]. These tumors are
primarily treated with surgical resection, with gross total re-
section curative in the majority of cases [2]. However, for
those cases that are not surgically curable, patients receive
radiation or chemotherapy [2]. Focal radiation with standard
doses of 45 to 54Gy are effective in long-term tumor
control, but cause serious side-effects, including decreased
intellectual function, endocrine deficits, secondary neo-
plasms, hearing loss and vasculopathy. As a result, the use
of radiation in young children is limited [3]. Chemotherapy
has been used as a first-line treatment to delay or replace
radiotherapy in certain situations, such as critical tumor
location, or in relapsed tumors after surgery [4, 5].
Vincristine, carboplatin and combinations of procarbazine,
thioguanine and lomustine are often used to treat pediatric
PAs that are not surgically curable. These treatments result
in 5-year event-free survival rates of 40–50% [6]. A common
consequence of chemotherapy is the development of multi-
drug resistance, with associated tumor relapse and progres-
sion. In this scenario, prognosis is very poor [7]. Primary
mechanisms for acquisition of drug resistance include over-
expression of ATP-binding cassette (ABC) transporters,
such as multidrug resistant protein 1 (MDR1, also known as
P-glycoprotein or P-gp), or multidrug resistance proteins
(MRPs) [7–9], which pump anticancer agents out of the
cells. In pediatric low-grade gliomas, including PAs, MDR1
mediated drug resistance is the main mechanism for chemo-
therapeutic resistance [10, 11]. Presently there is no clinically
effective treatment to compensate for the effects of MDR1,
even with substantial research addressing this need.
The cell surface marker, CD133, has been identified as a
putative stem cell marker in normal and malignant brain
tissues. CD133 and MDR1 co-express at high levels after
prolonged chemotherapy in pediatric medulloblastomas
[12] and ependymomas [11]. However, direct evidence
supporting a relationship between CD133 and MDR1 is
lacking. We previously identified enriched levels of CD133
positive cells in adult glioblastoma cultures subjected to
prolonged chemotherapy, and determined that CD133
regulates MDR1 expression via PI3K/AKT/NF-κB
signaling, in these cells [13]. Because CD133 positive cells
are present in pediatric low grade gliomas including PAs
[14, 15], in the present study we investigated the potential
relationship between CD133 and MDR1 in pediatric PAs,
with the goal of identifying therapeutic targets for recur-
rent tumors subsequent to chemotherapy.
Methods
Chemicals and reagents
Doxorubicin (Dox, Cat#44583), vinblastine (VIN,
Cat#V1377), vincristine (VCR, Cat#V8388) and verapamil
(Cat#V4629) were purchased from Sigma-Aldrich (St.
Louis, MI, USA) and prepared following manufacturer’s
instructions. CD133 expression plasmid pCMV6-CD133-
Myc-DDK, its control vector pCMV6-Myc-DDK, and trans-
fection reagent TurboFectin 8.0 were purchased from
Origene (Rockville, MD, USA). Human specific CD133
short interfering (si) RNA (oligonucleotide ID# HSS113055),
scrambled control siRNA oligonucleotide (12935-200), and
siRNA transfection reagent Lipofectamine® RNAiMAX were
purchased from Invitrogen (Life Technologies, Grand Island,
NY, USA).
Clinical samples
Data for 143 pediatric PA patients was reviewed from the
database of the Division of Pediatric Neurosurgery at Ann &
Robert H. Lurie Children’s Hospital (A&RLCH) (Additional
file 1). Fifteen patients who had primary and recurrent
tumor resection were selected for further analysis. Eight of
these patients did not receive adjuvant therapy, and are
labeled as negative controls; seven received chemotherapy
following resection and are labeled as the investigative group
(Fig. 1). Detailed clinical characteristics of these 15 patients
are presented in Table 1. Survival curves for these 15 pa-
tients and hazard ratio were plotted and analyzed using
GraphPad Prism 7 (GraphPad Software, Inc. La Jolla, CA
USA). Hematoxylin and eosin (H&E) stained sections from
formalin fixed paraffin-embedded (FFPE) primary and re-
lapsed tumors samples were independently reviewed by two
pediatric pathologists (N.W. and V. R.), using World Health
Organization 2007 criteria for tumor classification. Repre-
sentative slides were immunostained to evaluate MDR1 and
CD133 co-expression. The study was approved by the insti-
tutional review board (IRB) at A&RLCH.
Cell culture and induction of drug resistance
Pediatric PA cell lines Res186 and Res199 were gener-
ously provided by Dr. Silber (University of Washington,
Seattle, WA, USA) [16, 17]. Cells were grown as
Fig. 1 Selection of control and investigative groups
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monolayers in DMEM/F12 Ham’s medium + 10% FCS in
5% CO2. These cells are labeled as wild-type (WT).
Res186 and Res199 cell sublines resistant to doxorubicin
(DOX), vinblastine (VIN) or vincristine (VCR) were estab-
lished as previously described [18]. Briefly, drug resistant
cells were obtained by successive exposure to increasing
amounts of DOX (0.01 and 0.1 μg/ml), VIN (0.001, 0.01
and 0.1 μg/ml), or VCR (0.001, 0.01 and 0.1 μg/ml). Cells
that survived a minimum of five passages at the highest
drug dosage were used in this study. These cells were
labeled DOX-R, VIN-R and VCR-R and maintained in
complete culture medium with indicated drug.
Immunofluorescence
Formalin-fixed, paraffin-embedded (FFPE) slides for 15
primary PA tumor samples and paired relapsed tumors
from eight negative control and seven investigative pa-
tients were requested from the Department of Pathology
at A&RLCH under IRB protocol#2005-12252. Immuno-
fluorescence followed deparaffinization with 100% xylene
and ethanol. Antigen retrieval was performed by boiling
for 10 min in 0.01 M sodium citrate (pH 6.0) solution.
Endogenous peroxides were blocked with 3% hydrogen
peroxide, 10% donkey serum and 0.3% Triton X-100 in
PBS. The samples were incubated with rabbit polyclonal
MDR1 [EPR10364] (Abcam, ab170904, dilution 1:100)
and mouse monoclonal CD133 (Abcam, ab15580-100,
dilution 1:100) antibodies, to examine MDR1 and
CD133 co-expression. Secondary antibodies were donkey
anti-mouse cy3 or anti-rabbit Alexa Fluor 488 (dilution
1:200) (Jackson Lab, ME, USA). Nuclei were counter-
stained with 4′, 6-diamidino-2-phenylindole (DAPI).
Images were captured with light (Leica DMR-HC up-
right microscope), and confocal (Zeiss LSM 510) micros-
copy and analyzed using OpenLab 5.0 software.
For immunofluorescence of cultured cells, 5 × 103
Res186 and Res199 WT or drug resistant cells were
grown on 8-well chamber slides overnight and fixed with
4% paraformaldehyde in PBS (Pierce Chemical Co.,
Rockford, IL). Fixed cells were blocked with 10% donkey
serum and 0.3%Triton X-100 in PBS and incubated with
rabbit polyclonal MDR1 [EPR10364] for single staining; or
rabbit polyclonal MDR1 [EPR10364] (Abcam, ab170904,
1:100) and mouse monoclonal CD133 antibody (Abcam,
ab5558, 1:100) to observe co-expression. Alexa Fluor 488
or cy3 labeled secondary antibodies (dilution 1:200)
(Jackson Lab, ME, USA) were used for detection. Nuclei
were counterstained with DAPI. Images were captured
with a Leica DM-IRB inverted microscope and analyzed
using OpenLab 5.0 software.
Table 1 Patients characteristics






1 M 5 Spinal Cord 27 Alive
2 M 11 Spinal Cord 30 Deceased
3 M 2 Cerebellum 31 Alive
4 M 11/12 Cerebellum 8 Alive
5 F 4 Left Thalamic 19 Alive
6 M 16 Left intraventricular 58 Alive
7 F 13 Right Front Lobe 20 Alive




9 M 4 Cerebellum 8 CPL, VIN/12, TPCV/14 Alive
10 M 3 Left Temporal Lobe 13 CPL/4, VCR/4, VIN/10 Alive
11 F 4 Right Temporal Lobe 8 CPL/8, VCR/8 Alive
12 F 7 Spinal Cord 12 CPL/7, VCR/7, ISP/4 Deceased
13 F 1 Suprasellar/Third ventricle 46 CPL, VCR/4, VIN/9,
O6-BG & TMZ/2
Deceased
14 F 1 C4-T4 spinal cord 27 CPL, VCR, TMZ/12 Alive
15 M 7/12 Posterior Fossa 10 CPL, ETO, TAM/10 Deceased
aAge at initial diagnosis
bTime of relapse after first operation
cInitial chemotherapy/length of treatment (months) after first operation
Abbreviations: M male, F female, CPL carboplatin, VCR vincristine, VIN vinblastine, TPCV Thioguanine, Procarbazine, CCNU and Vincristine, ISP ispinesib, ETO
etoposide, TAM tamoxifen, O6-BG O6-Benzylguanine, TMZ temozolomide
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MTS assay for determination of cell viability
Cell viability was determined using the 3-(4, 5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) (Promega) assay with the results read on
an ELISA Reader from TECAN Sunrise™ (TECAN, CA,
USA). To determine cell viability of Res186 and Res199 WT
cells overexpressing CD133 in response to DOX, VIN or
VCR, 1 × 106 cells were plated in T25cm2 flasks 1 day prior
to pCMV6-Myc-DDK or pCMV6-CD133-Myc-DDK trans-
fection using TurboFectin 8.0 following manufactures’
protocol. The cells were harvested after 48 h, plated at 2 ×
104 cells/100 μl in 96-well plates with complete medium
containing 0.01 μg/ml DOX, VIN or VCR and incubated at
37 °C with 5% CO2. After 48 h MTS reagent was added and
cell viability was determined following manufactures
instructions.
To evaluate cell viability of Res186 and Res199 DOX-
R, VIN-R and VCR-R cells treated with 10 μM verapamil
(diluted with methanol), drug resistance cells were
grown in drug-free media and serum starved for 24 h,
then 5 × 103 cells were plated per well in 96-well plates
and incubated overnight in complete drug-free media.
The medium was then replaced with complete media
containing 10 μM verapamil or 10 μl methanol (dilution
solvent control) plus 0.1 μg/ml DOX, VIN or VCR. To
determine cell viability of drug resistant cells treated
with CD133 siRNA, 1 × 106 drug resistant cells were
plated in T25cm2 flasks 1 day prior to transfection with
siCD133 or control siRNA (final concentration 20nM)
using Lipofectamine® RNAiMAX following the reverse
transfection protocol, as per manufactures instructions.
The cells were harvested after 48 h, plated at 2 × 104
cells/100 μl in 96-well plates and incubated overnight in
complete drug-free media at 37 °C with 5% CO2. The
next day culture media was replaced with complete
medium containing 0.1 μg/ml DOX, VIN or VCR. After
72 h MTS reagent was added to verapamil or CD133
siRNA treated drug resistant cells and cell viability was
determined following manufactures instructions.
Each of the described treatments was repeated three
times in triplicate wells. Cell survival is presented as a
percentage of viable cells compared to corresponding vi-
able cell number in relevant dilution solvent or control
siRNA treatment groups normalized to one hundred
percent. Statistical analysis was carried out using Graph-
Pad Prism 7. P values were calculated using 2-sided
Student’s t test, with p < 0.05 considered significant.
Nuclear fragmentation and flow cytometry for detection
of apoptotic cells
To quantify nuclear fragmentation, 1 × 104 WT or drug
resistant cells/well were grown in complete or drug-free
media on 8-well chamber slides overnight. The following
day new media containing 0.01 μg/ml DOX, VIN or
VCR for WT cells or 10 μM verapamil plus 0.1 μg/ml
DOX, VIN or VCR for drug resistant cells was added to
the cells for 72 h. For studies examining the effects of
CD133 on nuclear fragmentation, WT cells were trans-
fected with pCMV6-CD133-Myc-DDK or pCMV6-Myc-
DDK using Turbofectin 8.0, then placed in complete
media containing 0.01 μg/ml DOX, VIN or VCR, for
48 h; drug resistant cells were treated with siCD133 or
control siRNA (final concentration 20nM) for 48 h,
using Lipofectamine® RNAiMAX, following the reverse
transfection protocol as per manufactures instruction,
then placed in complete media containing 0.1 μg/ml
DOX, VIN or VCR, for 72 h. After drug treatment cells
were washed with PBS and fixed with 4% paraformalde-
hyde in PBS (Pierce Chemical Co., Rockford, IL). Nuclei
were stained with DAPI. Images were captured from at
least five different fields per well with a Leica DM-IRB
inverted microscope and analyzed using OpenLab 5.0
software. Data from a minimum of three independent
wells was used to quantify the number of fragmented
nuclei, and the results were graphed with GraphPad
Prism 7 software. P values of less than 0.05 were consid-
ered statistically significant.
For flow-cytometry, 5 × 106 cells were grown in 10 cm
petri-dishes (BD Falcon) following the same treatment
protocol described for quantification of nuclear fragmen-
tation. Floating and attached cells were harvested, fixed
and stained with propidium iodide (PI, Life Technolo-
gies). Apoptotic cells were determined with sub-G1
flow-cytometric analysis by FACSCalibur flow cytometry
(BD Company). Data from a minimum of three inde-
pendent dishes was used to quantify the number of
apoptotic cells and graphed with GraphPad Prism 7 soft-
ware. P values of less than 0.05 were considered statisti-
cally significant.
Quantitative real- time PCR
5 × 104 Res186 and Res199 WT or drug resistant cells
were grown in 6-well plates (BD Falcon) and treated
following the protocol described for quantification of
nuclear fragmentation. Total RNA was isolated with
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA).
cDNA was synthesized with qScript cDNA SuperMix
(5 ×) (Quanta Biosciences, 95048-025) following real-
time (RT) PCR with human ABCB1 forward 5′-cccat-
cattgcaatagcagg-3′ and reverse 5′-gttcaaacttctgctcctga-
3′ primers and GAPDH forward 5′-tgacatcaagaaggtga-
3′ and reverse 5′-tccaccaccctgttgctgta-3′ primers as
described previously [13]. To ensure accuracy, an in-
ternal reference reaction was performed on the same
sample as used for the target gene. The results were
standardized with the formula: ΔCT = CTRef − CTTarget
and converted to folds of target gene over reference
gene (F = 2- ΔCT). Data from a minimum of 3
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independent experiments was used to quantify gene
expression. P values of less than 0.05 were considered
statistically significant.
Western blots
Archived PA tumor tissue specimens were requested
from the Falk Brain Tumor Tissue Bank, Division of
Pediatric Neurosurgery at A&RLCH under IRB protocol
#2005-12252. Total protein was extracted from tumor
tissue samples with Tissue Extraction Buffer I (Life
Technologies, Cat#FNN0071). For Res186 and Res199
WT or drug resistant cell lines total protein was ex-
tracted with Novex® NP40 Cell Lysis Buffer (Life Tech-
nologies, Cat#FNN0021) following manufacturer’s
instructions. Protein concentrations were quantified with
the BCA Protein Assay Kit (Thermo Scientific) with
Nanodrop 8000 (Thermo Scientific). Equal amounts of
cell lysate were resolved by SDS/PAGE and transferred
to nitrocellulose membranes (Bio-Rad). Blocking was
performed for 60 min with 5% nonfat dry milk in TBST,
followed by blotting with primary antibodies overnight at
4 °C. Primary antibodies included: rabbit polyclonal anti-
CD133 (ab19898, 1:500), rabbit polyclonal anti-MDR1
(ab129450, 1:500) or β-actin (1:3,000) from Abcam; rabbit
polyclonal anti-phosphorylation-serine 473-Akt (S473-
Akt) (1:1,000), rabbit polyclonal anti-phosphorylation
threonine 308-Akt (T308-Akt) (1:1,000), mouse monoclo-
nal anti-NF-κB/p65 (1:1,000) and rabbit polyclonal
phospho-NF-κB/p65 from Cell Signaling Technology; and
rabbit polyclonal anti-Akt (1:2,000), and rabbit polyclonal
anti-GAPDH (1:2,000) from Santa Cruz Biotechnology.
After extensive washing with TBST, membranes were in-
cubated for 1 h at RT with HRP-conjugated donkey anti-
rabbit antibody or donkey anti-mouse antibody (Santa
Cruz Biotechnology, 1:5,000), and signal was detected with
enhanced chemiluminescence substrate (Bio-Rad). The
average intensities of each standard protein band were
quantified using Photoshop CS5 (Adobe Systems Incorpo-
rated) and compared to band intensities of an internal
control protein, GAPDH. The results were column-
plotted using GraphPad Prism 7 software. P values of less
than 0.05 were considered statistically significant.
Results
CD133 and MDR1 expression increase in recurrent
pediatric PAs following chemotherapy
CD133 and MDR1 expression levels were examined in
paired primary and recurrent pediatric PA tumor tissue.
Immunofluorescence with anti-mouse CD133 and anti-
rabbit MDR1 antibodies showed CD133 and MDR1 co-
expressed in all tumors. Levels of these proteins were
similar in paired primary and recurrent tumors from
patients who did not receive chemotherapy, whereas
protein expression was markedly elevated in recurrent
tumors, compared to primary tumor samples, from
patients that received chemotherapy (Fig. 2a and b).
Western blots confirmed high CD133 and MDR1 ex-
pression in recurrent tumors following chemotherapy
(Fig. 2c), compared to primary tumors from the same
patients. These results indicate an association between
CD133 and MDR1 expression, with both increasing in
response to chemotherapy.
CD133 regulates MDR1 expression via PI3K/AKT/NF-κB
signaling in multidrug resistant adult glioblastoma cells [13].
To investigate this signaling pathway in recurrent pediatric
PAs, subsequent to chemotherapy, western blot analysis was
performed using protein extracts from archived tumor tis-
sues to detect signaling mediator expression and NF-κB ac-
tivation. The results show significantly higher protein
(CD133/ MDR1), AKT and phosphorylation levels present
in recurrent tumors following chemotherapy, relative to
primary tumor matched samples (Fig. 2c and d, Additional
file 2: Figure S1). Moreover, overall survival (hazard ratio:
0.14, p= 0.04) and progression free survival (hazard ratio:
0.10, p= 0.0075) of the investigative group who received
chemotherapy was lower than the control group without ad-
juvant treatment (Fig. 2e). These results suggest a role for
PI3K/AKT/NF-κB signaling in elevating CD133 and MDR1
expression in pediatric PAs that recur following chemother-
apy, similar to previous data in adult drug resistant glioblast-
oma. Elevated CD133/MDR1 levels most likely contribute
to poor patient prognosis.
Overexpression of MDR1 in drug resistant pediatric PA
cells
Pediatric PA Res186 and Res199 cells were used to in-
vestigate whether CD133 regulates MDR1 through
PI3K/AKT/NF-κB signaling. Res186 and Res199 cells
were treated with DOX, VIN and VCR to generate drug
resistant cells (DOX-R, VIN-R and VCR-R). Untreated
(labeled wild-type (WT)) Res186 and Res 199 cells are
relatively drug sensitive. DOX-R, VIN-R and VCR-R cells
exhibited morphological changes when viewed under light
and confocal microscopes. DOX-R cells were polygonal
with long cytoplasmic processes, while VIN-R and VCR-R
cells exhibited protrusions along the cytoplasmic mem-
brane (Fig. 3a, Bright field panels). Immunofluorescence
(Fig. 3a, fluorescence panels), real-time PCR (Fig. 3b) and
western blots (Fig. 3c) showed elevated ABCB1 gene,
which encodes MDR1, and higher levels of MDR protein
in drug resistant cells relative to WT, respectively.
To determine whether pharmacologic inhibition of
MDR1 influences resistant cell response to cytotoxic
treatments, DOX-R, VIN-R and VCR-R Res186 and
Res199 cells were synchronized overnight in serum-
free culture medium, which was then replaced with
complete culture medium containing 0.1 μg/ml of
DOX, VIN or VCR, with or without 10 μM verapamil,
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an MDR1 inhibitor [19, 20]. Cell viability and apop-
tosis were respectively examined with MTS 72 h after
treatment and DNA fragmentation analysis 48 h after
treatment. Cell viability markedly decreased in drug
resistant cells upon co-treatment with chemotherapy
plus verapamil (Fig. 3d). Moreover, levels of apoptotic
cells, indicated by labeling with DAPI (blue), in-
creased with treatments that included verapamil
(Fig. 3e and f ). Apoptosis levels were confirmed and
quantitated by flow cytometry (Additional file 3:
Fig. 2 CD133 and MDR1 are present at high levels in recurrent pediatric PAs post chemotherapy. a and b Representative images show CD133 and
MDR1 in primary and matched relapsed PAs without (a) and with chemotherapy (b). c Western blots showing protein expression and activation state
for PI3K/AKT/NF-κB signaling mediators in primary and matched relapsed PAs, with and without chemotherapy. d Quantification of western blots
showing overexpression of CD133 and MDR1 in recurrent PAs with chemotherapy, compared to matched primary tumors. e Overall (top panel) and
progression free (bottom panel) survival of PAs without (control group) or with chemotherapy (investigative group)
Fig. 3 MDR1 is overexpressed and plays a critical role in drug resistant pediatric PA Res186 and Res199 cells. a Light micrographs (bright field panels)
showing morphology and confocal micrographs (fluorescence panels) showing MDR1 expression with immunofluorescence in drug sensitive (WT), and
DOX-R, VIN-R and VCR-R pediatric PA Res186 and Res199 cells. Nuclei are labeled with DAPI (blue). b and c RT-PCR and western blots show ABCB1 (b) and its
encoded protein MDR1 (c) in WT and drug resistant Res186 and Res199 cells. d MTS assay showing decreased cell viability of DOX-R, VIN-R, and VCR-R
Res186 and Res199 cells in response to 0.1 μg/ml of DOX, VIN or VCR, without (control) or with 10 μM verapamil for 72 h. e and f Nuclei labeled with DAPI in
DOX-R, VIN-R, VCR-R Res186 and Res199 cells treated with 10 μM verapamil for 48 h, or non-verapamil treated controls; fragmentation is indicated by yellow
arrows (e), and quantitated (f). (For b, d and f, each column represents the mean± s.d. of a minimum of three independent experiments done in triplicate;
* p<0.05, ** p< 0.01)
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Figure S2A and B). Taken together, our results support in-
creased MDR1 expression in DOX-R, VIN-R and VCR-R
Res186 and Res199 cells, relative to WT and MDR1 influ-
ence on cell response to chemotherapy.
CD133 regulates MDR1 expression via the PI3K/AKT/NF-κB
signaling
CD133 expression increases in brain [13, 21, 22] and
other tumor cells following chemotherapy [23–25]. Fur-
ther, CD133 co-localizes with MDR1 after chemotherapy
in pediatric medulloblastoma [12] and ependymoma
[11]. As shown here, by immunofluorescence, CD133
and MDR1 co-localize and expression levels are elevated
in DOX-R, VIN-R and VCR-R Res186 and Res199 PA
cells, compared to WT (Fig. 4a).
We have previously shown that CD133 regulates
MDR1 expression through PI3K/AKT/NF-κB signaling
in adult GBM cells [13]. To determine whether this oc-
curs in drug resistant Res186 and Res199 PA cells, we
used western blot analysis. CD133, p-Akt (S473 and
T308), phospho-NF-κB/p65, and MDR1 all increased in
DOX-R, VIN-R and VCR-R cells, compared to WT cells
(Fig. 4b). Transfection of Res186 and Res199 WT cells
with pCMV6-CD133, elevated CD133 expression and in-
creased: ABCB1 transcript, which encodes MDR1
(Fig. 4c), p-Akt (S473 and T308), phospho-NF-κB/p65,
Fig. 4 CD133 promotes MDR1 expression through PI3K/AKT/NF-κB signaling in pediatric PA Res186 and Res199 cells and decreases cell chemosensitivity.
a CD133 and MDR1 co-localize in WT, DOX-R, VIN-R and VCR-R Res186 and Res199 cells (white arrows). bWestern blot results for CD133, total Akt, p-Akt (S473
and T308), NF-κB/p65, p-NF-κB/p65 and MDR1 in WT and Dox-R, VIN-R, VCR-R Res186 and Res199 cells. c and d Real-time PCR for ABCB1 and western blot
results for CD133, total Akt, p-Akt (S473 and T308), NF-κB/p65, p-NF-κB/p65 and MDR1 in WT Res186 and Res199 cells transfected with pCMV6-Myc-DDK
(pCNV6) and pCMV6-CD133-Myc-DDK (pCMVCD133). e and f Nuclear fragmentation and cell viability of WT Res186 and Res199 cells transfected with pCMV6-
Myc-DDK (pCNV6) and pCMV6-CD133-Myc-DDK (pCMV6-CD133) in response to 0.01 μg/ml DOX, VIN and VCR treatments for 48 h. (For c, e and f, each
column represents the mean± s.d. of a minimum of three independent experiments done in triplicate; * p< 0.01, ** p< 0.01)
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and MDR1 (Fig. 4d). Consequently CD133 overexpres-
sion decreased nuclear fragmentation (Fig. 4e) and in-
creased cell viability (Fig. 4f ) of WT Res186 and Res199
cells in response to 0.01 μg/ml DOX, VIN and VCR.
Taken together, the present results, along with our previ-
ous findings [13] implicate PI3K/AKT/NF-κB signaling as
being of central importance to the effect of CD133 on
MDR1 expression and hence chemosensitivity.
Targeting CD133 improves chemotherapeutic efficacy in vitro
CD133 regulates MDR1 in drug resistant glioblastoma
[13] and, as shown here, pediatric PA Res186 and Res199
cells. Given this relationship, down-regulation of CD133
should decrease MDR1 expression and increase tumor cell
chemosensitivity. To investigate this, drug resistant cells,
DOX-R, VIN-R and VCR-R, cultured in the presence of
the drug they had acquired resistance to, were treated with
siRNA against CD133. SiRNA treated cells were then ex-
amined for ABCB1 gene expression (real-time PCR), pro-
tein expression (western blots), apoptotic response
(nuclear fragmentation and flow-cytometry) and cell via-
bility (MTS assay). Down-regulation of CD133 in Res186
and Res199 drug resistant cells decreased ABCB1 gene
(Fig. 5a) and encoded protein expression (MDR1), and re-
duced p-Akt (S473 and T308), phospho-NF-κB/p65, and
CD133 (Fig. 5b). Furthermore flow-cytometry showed in-
creased numbers of apoptotic cells in drug resistant cells
treated with siCD133 (Fig. 5c), and fragmented nuclei
Fig. 5 Targeting CD133 improves chemotherapeutic efficacy in drug resistant Res186 and Res199 cells. a and b Real-time PCR and western blots
for ABCB1 gene expression and protein alterations of CD133, total Akt, p-Akt (S473 and T308), NF-κB/p65, p-NF-κB/p65 and MDR1 in DOX-R, VIN-R,
VCR-R Res186 and Res199 cells transfected with siCD133, compared to control (siCtrl) cells, respectively. c, d and e Apoptosis with quantitative analysis
by flow-cytometry, nuclear fragmentation and cell viability of DOX-R, VIN-R, VCR-R Res186 and Res199 cells transfected with siCD133 or siCtrlfor 48 h,
followed by continued treatment with 0.1 μg/ml of indicated drug for 72 h after transfection, respectively. (For a, c, d and e, each column represents
the mean ± s.d. of a minimum of three independent experiments done in triplicate; * p < 0.05, ** p < 0.01)
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increased in these cells, compared to cells treated with
control siRNA (Fig. 5d). Finally, cell viability of drug resist-
ant cells significantly decreased following siCD133 treat-
ment (Fig. 5e). In total, our results indicate that
suppressing CD133 expression increases chemotherapeu-
tic efficacy of drug resistant PA cells.
Discussion
CD133, AKT, NF-κB and MDR1 were examined in
matched primary and recurrent, with or without chemo-
therapy, PAs, from pediatric patients. These proteins were
present at higher levels in tumors that recurred following
chemotherapy (Fig. 2). Increased expression was also ob-
served in PA cell lines, Res186 and Res199, following
chemotherapy. MDR1 was regulated by CD133 through
PI3K-Akt-NF-κB signaling, consistent with our previous
findings in drug resistant adult glioblastoma [13]. These
results suggest that a novel adjuvant chemotherapeutic
regimen, including agents that inhibit CD133 expression
may improve prognosis for children with PAs that are not
surgically curable, through MDR1 down-regulation.
MDR1, mediated drug resistance is the most extensively
characterized drug resistance mechanism in brain tumors.
This ATP-driven transmembrane drug transporter decreases
intracellular drug accumulation through decreased drug up-
take and increased drug efflux. High ABCB1 gene expres-
sion, which encodes MDR1, is associated with chemo-
resistance and poor outcome in many types of brain tumors,
including medulloblastomas [26, 27], gliomas [28], ependy-
momas [29–31] and PAs [32]. However, the underlying basis
for increased MDR1, in response to chemotherapy, is poorly
understood. Chemotherapeutic drugs are known to induce
changes within histone proteins that are associated with
MDR1 promoter sequences, these changes include increased
histone 3 (H3) acetylation [33] and induction of methylated
H3 lysine (K) 4 [34], both of which enhance multidrug re-
sistance. Protein kinase C, RAS, p53, and MDM2 are known
to modulate MDR1 expression and phosphorylation [35].
CD133, a cell surface marker for neural stem cells, is
present in malignant brain tumor tissues. Transplantation
of CD133 positive tumor cells, but not CD133 negative
cells, into NOD/SCID or nude mice produces tumors that
are similar to patient tumors from which they were
derived [36, 37]. Moreover, CD133 positive tumor cells
possess enhanced chemo- and radio-resistance, and con-
tribute to tumor recurrence and progression [38–40].
The purpose of this study was to examine MDR1,
CD133, and their potential interaction in pediatric PAs,
using both patient samples and PA cell lines Res186 and
Res199. Previous studies have shown CD133 positive
cells in adult and pediatric low-grade gliomas including
pediatric PAs [14, 15] and Res186 cells [16]. In this
study, CD133 positive cells were found to be present at
low levels in primary and recurrent tumors from patients
not receiving chemotherapy. In contrast, CD133 levels
were substantially elevated in relapsed tumors from PA
patients that received chemotherapy. MDR1 expression
levels in patient PAs were paralleled by CD133 levels. Ele-
vation of CD133 expression in recurrent tumors following
chemotherapy may be due to selection of a pre-existing
subpopulation of CD133+ cells, or through induction of
CD133 expression, or both. The basis for induced expres-
sion is poorly understood, but increasing evidence sug-
gests involvement of tumor microenvironment and
epigenetic factors [41–43]. For instance, hypoxia, in re-
sponse to chemotherapeutic agents, affects CD133 expres-
sion [41], and CpG hypomethylation of CD133 promoter
sequences, as well as methylation of histone H3 K4 and
K27 residues, known to upregulate CD133 [42–44].
Two PA cell lines Res186 and Res199 were used to in-
vestigate whether CD133 has a regulatory role in MDR1
overexpression. Drug resistant Res186 and Res199 cell
lines were developed by extended treatment with DOX,
VIN or VCR. As in observed in recurrent pediatric tumors
treated with chemotherapy, CD133 positive cells increased
in drug resistant cells. Furthermore, drug-resistant cells
showed elevated MDR1 expression. Suppressing CD133
expression in these cells decreased MDR1. Western blot
results suggest that CD133 may impact MDR1 levels
through PI3K-Akt-NF-κB signaling. The findings in this
study, in combination with other reports, support the pos-
sibility that CD133 positive cells are involved in tumori-
genesis and recurrence in pediatric PAs.
Conclusions
In conclusion the results presented support a critical
role for CD133 in chemotherapy, not only in malignant
brain tumors, as suggested previously, but also in low-
grade gliomas including pediatric PAs. Future studies
should focus on the development of a two-pronged che-
motherapeutic approach, targeting CD133 and MDR1 as
a means to eradicate CD133 positive drug resistant cells
and ultimately improve treatment outcomes for patients
with brain tumors, including recurrent PAs.
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